Deepak et al. found that the expression of SRSF3 decreased in early human liver diseases, including nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), or cirrhosis 104. This evidence concerns the gene SRSF3 and metabolic dysfunction-associated steatotic liver disease.